PepGen Inc
NASDAQ:PEPG
Intrinsic Value
PepGen Inc is a US-based company operating in Biotechnology industry. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of PEPG.
PepGen Inc's market capitalization is 386m USD.
PEPG stock price is 11.93 USD.
PEPG.
PEPG. Open DCF Valuation
PEPG. Open Relative Valuation
PEPG has upside potential of 85% compared to the average analyst price target.
Open Wall St Estimates
PEPG has negative Free Cash Flow for the last twelve months.
PEPG has negative Operating Income for the last twelve months.
PEPG has negative Net Income for the last twelve months.
PEPG's ROE (Return on Equity) for the past 12 months is negative and is equal to -55%.
PEPG's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -258%.
PEPG has negative three-year average ROE (Return on Equity): -40%. The company is not efficient at transforming stockholders' equity into net income.
PEPG has negative three-year average ROIC (Return on Invested Capital): -502%. The company is not efficient at using invested capital to generate operating income.
PEPG's short-term assets (113m USD) exceed its short-term liabilties (18m USD).
PEPG's long-term assets (143m USD) exceed its long-term liabilties (35m USD).
PEPG's D/E (Debt to Equity) is very low and is equal to 0.
PEPG's Altman Z-Score is very low and is equal to -0.05.
Fundamental Analysis
PepGen Inc
Balance Sheet Decomposition
PepGen Inc
| Current Assets | 112.7m |
| Cash & Short-Term Investments | 110.4m |
| Other Current Assets | 2.3m |
| Non-Current Assets | 30.4m |
| PP&E | 28.4m |
| Other Non-Current Assets | 2m |
| Current Liabilities | 17.5m |
| Accounts Payable | 1m |
| Accrued Liabilities | 16.5m |
| Non-Current Liabilities | 17.1m |
| Other Non-Current Liabilities | 17.1m |
Earnings Waterfall
PepGen Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-84.8m
USD
|
|
Operating Income
|
-84.8m
USD
|
|
Other Expenses
|
6.1m
USD
|
|
Net Income
|
-78.6m
USD
|
Free Cash Flow Analysis
PepGen Inc
PEPG Profitability Score
Profitability Due Diligence
PepGen Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
PepGen Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
PEPG Solvency Score
Solvency Due Diligence
PepGen Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Score
PepGen Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PEPG Price Targets Summary
PepGen Inc
According to Wall Street analysts, the average 1-year price target for
PEPG
is 22.03 USD
with a low forecast of 19.19 USD and a high forecast of 27.3 USD.
Ownership
PEPG Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
PEPG Price
PepGen Inc
| Average Annual Return | 11.08% |
| Standard Deviation of Annual Returns |
N/A
|
| Max Drawdown | -78% |
| Market Capitalization | 378.5m USD |
| Shares Outstanding | 32 354 500 |
| Percentage of Shares Shorted | 2.37% |
Company Profile
PepGen Inc
Country
Industry
Market Cap
Dividend Yield
Description
PepGen Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Boston, Massachusetts and currently employs 31 full-time employees. The company went IPO on 2022-05-06. PepGen Inc. is a clinical-stage biotechnology company advancing the oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases. Its proprietary enhanced delivery oligonucleotides (EDOs) are designed to target the underlying causes of rare genetic diseases, such as duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). The firm through its enhanced delivery oligonucleotide (EDO) platform developing a pipeline of disease-modifying peptide-conjugated oligonucleotide candidates to treat a variety of degenerative neuromuscular diseases. Its lead product candidates include PGN-EDO51 and PGN-EDODM1. Its lead product candidate PGN-EDO51, is an EDO peptide conjugated to a phosphorodiamidate morpholino oligomer (PMO) therapeutic cargo, which is developed for the treatment of DMD patients with mutations amenable to exon 51-skipping approach. The firm is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, for the treatment of DM1.
You don't have any saved screeners yet
